Amoy Diagnostics Co., Ltd. (SHE:300685)

Market Cap	8.17B
Revenue (ttm)	1.15B
Net Income (ttm)	281.14M
Shares Out	386.86M
EPS (ttm)	0.71
PE Ratio	29.75
Forward PE	23.53
Dividend	0.30 (1.40%)
Ex-Dividend Date	Jun 3, 2025

Volume	2,894,385
Average Volume	7,955,563
Open	20.84
Previous Close	21.11
Day's Range	20.84 - 21.30
52-Week Range	17.20 - 28.79
Beta	0.69
RSI	49.18
Earnings Date	Jul 28, 2025

About Amoy Diagnostics

Amoy Diagnostics Co., Ltd. engages in the development and commercialization of diagnostics product for oncology in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers, and advances targeted treatment research in ovarian cancer; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a CGP assay; AmoyDx BRCA Pro panel, covers various protein coding regions, intron/exon boundaries, sele...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2008
• Employees: 1,144
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300685

Financial Performance

In 2024, Amoy Diagnostics's revenue was 1.11 billion, an increase of 6.27% compared to the previous year's 1.04 billion. Earnings were 254.86 million, a decrease of -2.53%.